Urogen Pharma (NASDAQ:URGN) Issues Earnings Results

Urogen Pharma (NASDAQ:URGN) issued its quarterly earnings data on Wednesday. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02), FiscalAI reports. The business had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $50.4 million in Q2, up 73% sequentially, with 1,444 activated accounts, 452 prescribers, and repeat prescribers representing approximately 45% of writers. Community practices accounted for about 55% of utilization, supporting the company’s view that adoption remains in an early growth phase.
• UroGen reported durable ZUSDURI clinical results, with 64.5% of complete responders estimated to remain disease-free at 36 months and median response duration not yet reached. Management said real-world physician experience is increasingly supporting use beyond patients who are poor surgical candidates.
• JELMYTO revenue was stable at $22 million, and the company maintained its 2026 guidance of $97 million to $101 million. However, management has not yet observed a meaningful “reverse halo” effect from the ZUSDURI launch on JELMYTO demand.
• UroGen expects to submit the UGN-103 NDA within weeks, complete UGN-104 enrollment by year-end, and begin a UGN-501 Phase I study later in 2026. A patent allowance covering ZUSDURI and UGN-103 is expected to provide protection through July 2044.
• Full-year operating expense guidance increased to $260 million-$270 million as UroGen accelerates ZUSDURI promotional and patient-awareness spending and advances pipeline programs. Management remains confident it can reach profitability with existing capital resources, but the higher investment is expected to pressure near-term results.

Urogen Pharma Trading Up 3.8%

Shares of URGN traded up $1.75 during mid-day trading on Friday, reaching $47.35. The company’s stock had a trading volume of 349,772 shares, compared to its average volume of 795,528. The stock has a market cap of $2.31 billion, a PE ratio of -23.98 and a beta of 1.57. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $48.19. The company’s fifty day moving average price is $36.07 and its two-hundred day moving average price is $26.98.

Analyst Ratings Changes

Several brokerages have weighed in on URGN. UBS Group restated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. Guggenheim boosted their target price on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday. TD Cowen increased their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Oppenheimer boosted their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.78.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider owned 119,763 shares in the company, valued at $4,790,520. This trade represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. grew its holdings in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the period. Tower Research Capital LLC TRC raised its position in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. Nebula Research & Development LLC bought a new position in Urogen Pharma during the 2nd quarter valued at approximately $162,000. Finally, Man Group plc purchased a new stake in Urogen Pharma in the 2nd quarter worth approximately $196,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.